Perturbations in PI3K pathway and cyclin dependent kinase (CDK) pathway to predict complete responders in CRC patients treated with ADAPT therapy.

3610 Background: Aspirin or selective COX-2 inhibitormay improve overall survival (OS) in colorectal cancer (CRC) patients with PIK3CA mutations. However, routine use of anti-inflammatory agents in metastatic CRC patients remains controversial. We showed that 3-year maintenance celecoxib, also a stemness inhibitor coupled with capecitabinein a two-step ADAPT (activating dormant tumor cells and potentiate targeting) therapy led to 40% complete responders (CR) whose median survival reached 92.7 months in patients with unresectable stage IV CRC (Lin et al. AACR LBA254). We sought to determine genetic aberrations and related pathways as predictor of CR to ADAPT therapy. Methods: We retrospectively reviewed 50 consecutive stage IV CRC patients who had achieved CR with ADAPT therapy alone or in conjunction with metastectomy between 2006-2012 at University of Washington. All patients were tested for a panel of 199 cancer-related genes (UW Oncoplex) with Illumina deep sequencingplatform Results: We select firs...